Skip to content
MarketScale
‹ Back to IndustriesSciences

The Industry That is Depending on Science and Regulation to Grow

Yuran Li, Director of MS Commercial Strategies at Alternative Biomedical Solutions, plays a pivotal role in cannabis testing and method development, addressing the complexities of cannabis as a consumable product. As more states legalize cannabis, rigorous testing is necessary to ensure safety and proper labeling due to the plant's tendency to absorb harmful substances like pesticides and heavy metals.

This story was produced through MarketScale. See how Sciences teams put it to work with Executive Thought Leadership.

By Jason Claybrook · Alternative Biomedical SolutionsCannabinoidCannabisCannabis Testing
Share
The Industry That is Depending on Science and Regulation to Grow

Key takeaways

01

Alternative Biomedical Solutions is a pioneer in cannabis method development and testing.

02

Yuran Li emphasizes the importance of rigorous cannabis testing due to its unique absorption of pesticides and heavy metals.

03

Different states have varied laws on cannabis sales, making it essential to understand individual state regulations.

Yuran Li, Director, MS Commercial Strategies, Alternative Biomedical Solutions (ABS), is a biochemist by training. Still, his fascinations with physics, math, and probability have led him down some interesting paths, including some stints in the professional poker world. Lucky for ABS, he chose the science route.

Cannabis is a schedule 1 drug classification by the U.S. Federal government. As more and more states legalize it, there is a growing need for reliable testing to ensure the safety and potency of cannabis products. ABS is one of the pioneers in cannabis method development and testing. Li spoke with Jason Claybrook on some of ABS’s activities surrounding Cannabis.

Any product that people consume goes through testing to ensure their safety. “Cannabis is unique in that it’s ultimately a weed,” Li said. And it can prove quite a challenge to cultivate because the plant can soak up a lot of pesticides and other elements used for pest control. “Additionally, the Cannabis plant itself also uptakes quite a lot of heavy metals, things like arsenic and lead.” Accumulation of these pollutants can harm humans, so accurate testing is essential.

Some of the testing ABS does on Cannabis is to look for micro toxins, like mold and soil pollutants. And from a marketing and regulatory standpoint, they test for potency. In some cases, testing can help ensure that a strain grown for CBD does not contain THC. One challenge Li cautioned is every state has different guidelines, and it is essential to understand the laws governing each state where Cannabis sales are allowed.

Another aspect of lab testing that is becoming more and more important for Cannabis is label testing. As with craft beers and whiskey, labels need to back up their product’s claims. Testing ensures the strain offered on the label is the strain received by the consumer.

Breaking through ‘Pilot Purgatory’ in Innovating New Solutions

Is Cryptocurrency and Its Tech Infrastructure Ready for a Revolution?

About the author

JC
Jason Claybrook

Sciences: are you visible to AI?

Before they reach out, Sciences buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Sciences expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's Sciences expertise into the articles, video, and social content B2B marketing buyers in your industry are searching for. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Sciences Insights

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

The pharmaceutical industry is facing a significant challenge as over $300 billion in branded pharmaceutical revenue is set to lose patent protection by 2030. This revenue gap is driving the largest merger and acquisition cycle seen in a decade, with companies seeking external growth through acquisitions. This shift is impacting the entire life sciences supply chain, prompting strategic changes across the industry.

  • 01Over $300 billion in pharmaceutical revenue is at risk due to patent expirations by 2030.
  • 02Big Pharma is engaging in an aggressive cycle of mergers and acquisitions.
  • 03The acquisitions are reshaping the life sciences supply chain.

Jun 29, 2026

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences launches Phase I study of what it calls the first AI-formulated drug in the clinic

Quotient Sciences has initiated a Phase I clinical study at its UK facility for an oral solid dose formulation designed using artificial intelligence — what the company believes is the first AI-formulated drug to reach human clinical evaluation. The study, cleared by the UK's Medicines and Healthcare products Regulatory Agency, will assess safety and pharmacokinetics in healthy volunteers. The program, which used Intrepid Labs' machine learning algorithm, signals a broader shift in how contract drug development organizations are integrating AI across formulation and clinical workflows.

  • 01Quotient Sciences initiated a Phase I study of an AI-designed oral solid dose formulation at its UK facility following MHRA approval — the first such case the company believes has been reported.
  • 02The formulation was developed using Intrepid Labs' advanced machine learning algorithm in combination with Quotient Sciences' Translational Pharmaceutics platform.
  • 03The milestone is part of a broader CRDMO strategy to embed AI-enabled approaches across formulation development and clinical workflows, with implications for the wider contract pharma sector.

Jun 17, 2026

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences launches Phase I trial of what it calls the first AI-formulated drug to reach the clinic

Quotient Sciences has initiated a Phase I clinical study of an oral solid dose formulation designed using AI, cleared by the UK's MHRA and conducted at the company's UK facility. The trial—built on machine learning algorithms from partner Intrepid Labs and Quotient's Translational Pharmaceutics platform—aims to validate AI as a direct contributor to formulation design rather than just an upstream analytical tool. Benchling characterizes the broader moment as biotech entering a "builder phase," in which leading organizations embed AI capability at the bench level rather than running isolated pilots.

  • 01Quotient Sciences has dosed healthy volunteers in a Phase I study it describes as the first clinical evaluation of an AI-designed oral formulation, following approval from the UK's MHRA.
  • 02The formulation was developed using advanced machine learning algorithms from Intrepid Labs, integrated with Quotient Sciences' Translational Pharmaceutics platform.
  • 03Benchling identifies a sector-wide shift toward embedding AI capability directly at the bench, moving beyond isolated pilots to structural adoption across biotech R&D.

Jun 17, 2026

Explore More Sciences Insights

Read more expert perspectives from across Sciences.

Browse Sciences Hub

About the Experts

YL
Yuran Li

Director, MS Commercial Strategies

Alternative Biomedical Solutions (ABS)

Yuran Li is a biochemist by training with a fascination for physics, math, and probability, and has had professional experience in the poker world. At ABS, he plays a key role in cannabis method development and testing.

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Sciences and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512